Mark R. Nathan
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study.
Journal: BMC cancer
Published: March 28, 2025
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.
Journal: British journal of cancer
Published: May 05, 2023
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.
Journal: British journal of cancer
Published: November 14, 2022
The CVS Effect on American Health Insurance.
Journal: Managed care (Langhorne, Pa.)
Published: March 30, 2018
The emerging world of breast cancer immunotherapy.
Journal: Breast (Edinburgh, Scotland)
Published: May 21, 2017
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Journal: The Journal of pathology
Published: May 09, 2016
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
Journal: Nature medicine
Published: March 24, 2016
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Journal: Molecular cancer therapeutics
Published: February 27, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026